LawPlayer
My bookmarksSign up freeSign up free
Source

Commission Delegated Regulation (EU) 2017/579 of 13 June 2016 supplementing Regulation (EU) No 600/2014 of the European Parliament and of the Council on markets in financial instruments with regard to regulatory technical standards on the direct, substantial and foreseeable effect of derivative contracts within the Union and the prevention of the evasion of rules and obligations (Text with EEA relevance. )

Commission Delegated Regulation (EU) 2017/579 of 13 June 2016 supplementing Regulation (EU) No 600/2014 of the European Parliament and of the Council on markets in financial instruments with regard to regulatory technical standards on the direct, substantial and foreseeable effect of derivative contracts within the Union and the prevention of the evasion of rules and obligations (Text with EEA relevance. )

Delegated Regulation (EU) 2017/579 · Regulation · 4 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Definitions

Article 1

Open ↗

For the purposes of this Regulation the following definition shall apply:   ‘guarantee’ means an explicitly documented legal obligation by a guarantor to cover payments of the amounts due or that may become due pursuant to the OTC derivative contracts covered by that guarantee and entered into by the guaranteed entity in favour of the beneficiary where there is a default as defined in the guarantee or where no payment has been effected by the guaranteed entity.

Contracts with a direct, substantial and foreseeable effect within the Union

Article 2

Open ↗

1.   An OTC derivative contract shall be considered as having a direct, substantial and foreseeable effect within the Union when at least one third country entity benefits from a guarantee provided by a financial counterparty established in the Union which covers all or part of its liability resulting from that OTC derivative contract, to the extent that the guarantee meets both following conditions: (a) it covers the entire liability of a third country entity resulting from one or more OTC derivative contracts for an aggregated notional amount of at least EUR 8 billion or the equivalent amount in the relevant foreign currency, or it covers only a part of the liability of a third country entity resulting from one or more OTC derivative contracts for an aggregated notional amount of at least EUR 8 billion or the equivalent amount in the relevant foreign currency divided by the percentage of the liability covered; (b) it is at least equal to 5 per cent of the sum of current exposures, as defined in Article 272(17) of Regulation (EU) No 575/2013 of the European Parliament and of the Council  ( 5 ) , in OTC derivative contracts of the financial counterparty established in the Union issuing the guarantee. 2.   When the guarantee is issued for a maximum amount which is below the threshold set out in paragraph 1(a), the contracts covered by that guarantee shall not be considered to have a direct, substantial and foreseeable effect within the Union unless the amount of the guarantee is increased, in which case the direct, substantial and foreseeable effect of the contracts within the Union shall be re-assessed by the guarantor against the conditions set out in points (a) and (b) of paragraph 1 on the day of the increase. 3.   Where the liability resulting from one or more OTC derivative contracts is below the threshold set out in paragraph 1(a), such contracts shall not be considered to have a direct, substantial and foreseeable effect within the Union even where the maximum amount of the guarantee covering such liability is equal to or above the threshold set out in paragraph 1(a) and even where the condition set out in paragraph 1(b) has been met. 4.   In the event of an increase in the liability resulting from the OTC derivative contracts or of a decrease of the current exposure, the guarantor shall re-assess whether the conditions set out in paragraph 1 are met. Such assessment shall be done respectively on the day of the increase of liability for the condition set out in paragraph 1(a), and on a monthly basis for the condition set out in paragraph 1(b). 5.   OTC derivative contracts for an aggregate notional amount of at least EUR 8 billion or the equivalent amount in the relevant foreign currency concluded before a guarantee is issued or increased, and subsequently covered by a guarantee that meets the conditions set out in paragraph 1, shall be considered as having a direct, substantial and foreseeable effect within the Union. 6.   An OTC derivative contract shall be considered as having a direct, substantial and foreseeable effect within the Union where the two entities established in a third country enter into the OTC derivative contract through their branches in the Union and would qualify as financial counterparties if they were established in the Union.

Cases where it is necessary or appropriate to prevent the evasion of rules or obligations provided for in Regulation (EU) No 600/2014

Article 3

Open ↗

1.   An OTC derivative contract shall be deemed to have been designed to circumvent the application of any provision of Regulation (EU) No 600/2014 if the way in which that contract has been concluded is considered, when viewed as a whole and having regard to all the circumstances, to have as its primary purpose the avoidance of the application of any provision of that Regulation. 2.   For the purposes of paragraph 1, a contract shall be considered as having for primary purpose the avoidance of the application of any provision of Regulation (EU) No 600/2014 if the primary purpose of an arrangement or series of arrangements related to the OTC derivative contract is to defeat the object, spirit and purpose of any provision of Regulation (EU) No 600/2014 that would otherwise apply including when it is part of an artificial arrangement or artificial series of arrangements. 3.   An arrangement that intrinsically lacks business rationale, commercial substance or relevant economic justification and consists of any contract, transaction, scheme, action, operation, agreement, grant, understanding, promise, undertaking or event shall be considered an artificial arrangement. The arrangement may comprise more than one step or part.

Entry into force and application

Article 4

Open ↗

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union . It shall apply from 3 January 2018.

Other acts of the same type
Council Implementing Regulation (EU) 2024/338 of 16 January 2024 implementing Regulation (EU) 2016/1686 imposing additional restrictive measures directed against ISIL (Da’esh) and Al-Qaeda and natural and legal persons, entities or bodies associated with themCommission Regulation (EU) 2024/234 of 15 January 2024 amending Annex I to Regulation (EC) No 1334/2008 of the European Parliament and of the Council as regards the removal of certain flavouring substances from the Union listCommission Implementing Regulation (EU) 2024/235 of 15 January 2024 approving Alkyl (C12-16) dimethylbenzyl ammonium chloride (ADBAC/BKC (C12-C16)) as an existing active substance for use in biocidal products of product-type 2 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the CouncilCommission Regulation (EU) 2024/238 of 15 January 2024 amending Annex I to Regulation (EC) No 1334/2008 of the European Parliament and of the Council as regards the introduction of restrictions on the use of certain flavouring substancesCommission Implementing Regulation (EU) 2024/239 of 15 January 2024 correcting and amending Implementing Regulations (EU) 2022/1421, (EU) 2022/652, (EU) 2022/1490 and (EU) 2022/320Commission Implementing Regulation (EU) 2024/353 of 15 January 2024 concerning the classification of certain goods in the Combined NomenclatureCommission Implementing Regulation (EU) 2024/356 of 15 January 2024 entering a name in the register of traditional specialities guaranteed (Bœuf traditionnel de race Normande (TSG))Commission Delegated Regulation (EU) 2024/950 of 15 January 2024 amending Delegated Regulation (EU) 2019/1602 as regards the date of application and the cases where customs authorities are required to deduct the quantities stated in the customs declaration from the total allowed quantity declared in the Common Health Entry Document (CHED)Commission Implementing Regulation (EU) 2024/220 of 12 January 2024 concerning the renewal of the authorisation of a preparation of Pediococcus pentosaceus NCIMB 30168 as a feed additive for all animal species and amending Implementing Regulation (EU) No 1119/2012Commission Implementing Regulation (EU) 2024/221 of 12 January 2024 concerning the renewal of the authorisation of a preparation of endo-1,4-beta-xylanase, endo-1,3(4)-beta-glucanase and endo-1,4-beta-glucanase, produced by Trichoderma reesei ATCC 74444, as a feed additive for all poultry species for fattening, all poultry species for laying and weaned piglets (holder of authorisation: DSM Nutritional Products) and amending Implementing Regulation (EU) No 403/2013Commission Implementing Regulation (EU) 2024/228 of 12 January 2024 concerning the authorisation of a preparation of Companilactobacillus farciminis CNCM I-3740 as a feed additive for chickens for fattening and turkeys for fattening (holder of authorisation: ChemVet dk A/S) and amending Regulation (EC) No 1876/2006Commission Implementing Regulation (EU) 2024/231 of 12 January 2024 concerning the authorisation of a preparation of halofuginone hydrobromide (Stenorol) as a feed additive for chickens for fattening, turkeys for fattening and turkeys reared for breeding (holder of authorisation: Huvepharma NV)

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

Contents

What to look at next